These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 30909550)

  • 1. Integrating Germline and Somatic Mutation Information for the Discovery of Biomarkers in Triple-Negative Breast Cancer.
    Wu J; Mamidi TKK; Zhang L; Hicks C
    Int J Environ Res Public Health; 2019 Mar; 16(6):. PubMed ID: 30909550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delineation of the Germline and Somatic Mutation Interaction Landscape in Triple-Negative and Non-Triple-Negative Breast Cancer.
    Wu J; Mamidi TKK; Zhang L; Hicks C
    Int J Genomics; 2020; 2020():2641370. PubMed ID: 32724790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deconvolution of the Genomic and Epigenomic Interaction Landscape of Triple-Negative Breast Cancer.
    Wu J; Mamidi TKK; Zhang L; Hicks C
    Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31683572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating germline and somatic variation information using genomic data for the discovery of biomarkers in prostate cancer.
    Mamidi TKK; Wu J; Hicks C
    BMC Cancer; 2019 Mar; 19(1):229. PubMed ID: 30871495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between Germline and Somatic Mutated Genes in Aggressive Prostate Cancer.
    Mamidi TKK; Wu J; Hicks C
    Prostate Cancer; 2019; 2019():4047680. PubMed ID: 31007957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline TP53 and MSH6 mutations implicated in sporadic triple-negative breast cancer (TNBC): a preliminary study.
    Yi D; Xu L; Luo J; You X; Huang T; Zi Y; Li X; Wang R; Zhong Z; Tang X; Li A; Shi Y; Rao J; Zhang Y; Sang J
    Hum Genomics; 2019 Jan; 13(1):4. PubMed ID: 30630526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unraveling the Genomic-Epigenomic Interaction Landscape in Triple Negative and Non-Triple Negative Breast Cancer.
    Wu J; Mamidi TKK; Zhang L; Hicks C
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies.
    Ma D; Jiang YZ; Xiao Y; Xie MD; Zhao S; Jin X; Xu XE; Shao ZM
    Cancer; 2020 Jul; 126(14):3209-3218. PubMed ID: 32383785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
    Hoyer J; Vasileiou G; Uebe S; Wunderle M; Kraus C; Fasching PA; Thiel CT; Hartmann A; Beckmann MW; Lux MP; Reis A
    BMC Cancer; 2018 Sep; 18(1):926. PubMed ID: 30257646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating Genomic Information with Tumor-Immune Microenvironment in Triple-Negative Breast Cancer.
    Otohinoyi D; Kuchi A; Wu J; Hicks C
    Int J Environ Res Public Health; 2022 Oct; 19(21):. PubMed ID: 36360779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
    Phuah SY; Looi LM; Hassan N; Rhodes A; Dean S; Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Nov; 14(6):R142. PubMed ID: 23116406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Features and Functional Implications of Germline Variants in Triple-Negative Breast Cancer.
    Ma D; Chen SY; Ren JX; Pei YC; Jiang CW; Zhao S; Xiao Y; Xu XE; Liu GY; Hu X; Liang XZ; Yu KD; Li DQ; Jiang YZ; Shao ZM
    J Natl Cancer Inst; 2021 Jul; 113(7):884-892. PubMed ID: 33151324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
    Rashid MU; Muhammad N; Bajwa S; Faisal S; Tahseen M; Bermejo JL; Amin A; Loya A; Hamann U
    BMC Cancer; 2016 Aug; 16(1):673. PubMed ID: 27553291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elucidation of the Genomic-Epigenomic Interaction Landscape of Aggressive Prostate Cancer.
    Kumar Mamidi TK; Wu J; Hicks C
    Biomed Res Int; 2021; 2021():6641429. PubMed ID: 33511206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing.
    Shimelis H; LaDuca H; Hu C; Hart SN; Na J; Thomas A; Akinhanmi M; Moore RM; Brauch H; Cox A; Eccles DM; Ewart-Toland A; Fasching PA; Fostira F; Garber J; Godwin AK; Konstantopoulou I; Nevanlinna H; Sharma P; Yannoukakos D; Yao S; Feng BJ; Tippin Davis B; Lilyquist J; Pesaran T; Goldgar DE; Polley EC; Dolinsky JS; Couch FJ
    J Natl Cancer Inst; 2018 Aug; 110(8):855-862. PubMed ID: 30099541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
    Brianese RC; Nakamura KDM; Almeida FGDSR; Ramalho RF; Barros BDF; Ferreira ENE; Formiga MNDC; de Andrade VP; de Lima VCC; Carraro DM
    Breast Cancer Res Treat; 2018 Feb; 167(3):803-814. PubMed ID: 29116469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline mutations of multiple breast cancer-related genes are differentially associated with triple-negative breast cancers and prognostic factors.
    Hata C; Nakaoka H; Xiang Y; Wang D; Yang A; Liu D; Liu F; Zou Q; Wei L; Zheng K; Inoue I; You H
    J Hum Genet; 2020 Jul; 65(7):577-587. PubMed ID: 32029870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic landscape in mutational triple negative breast cancer.
    Shi Y; Jin J; Ji W; Guan X
    Mol Cancer; 2018 Jul; 17(1):99. PubMed ID: 30007403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast cancer patients.
    De Brakeleer S; De Grève J; Desmedt C; Joris S; Sotiriou C; Piccart M; Pauwels I; Teugels E
    Clin Genet; 2016 Mar; 89(3):336-40. PubMed ID: 26010302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of BRCA1 somatic mutations and response to neoadjuvant chemotherapy in Chinese women with triple-negative breast cancer.
    Li M; Zhang J; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Gene; 2016 Jun; 584(1):26-30. PubMed ID: 26956035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.